BRD4 degrader AT1 is primarily utilized in the field of cancer research and therapy. It functions by targeting and degrading the BRD4 protein, which plays a critical role in the regulation of gene expression, particularly in cancer cells. By degrading BRD4, this compound effectively disrupts the transcription of oncogenes, leading to the inhibition of cancer cell proliferation and survival. This makes it a promising tool for studying and treating cancers that are driven by BRD4-dependent pathways, such as certain types of leukemia and solid tumors. Additionally, its application extends to exploring epigenetic mechanisms and developing targeted therapies for diseases where BRD4 overexpression is a contributing factor.